TelyRx Holdings Inc. saw a significant drop in its stock price, closing down 6.12% in the latest trading session.
In the latest market session, TelyRx Holdings Inc. (TELY.TO) experienced a notable decline, closing at CA$2.30, down 6.12%. This downturn raises questions about the company's current performance and investor sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$66.45M
52W high
$4.25
52W low
$2.00
1W change
+2.94%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 144.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+144.9% Upside
Current Price
C$2.45
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
83.1%
Annualized
90-Day Vol
92.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.31 | C$1.73 โ C$3.07 |
| 60 trading days | C$2.18 | C$1.45 โ C$3.26 |
| 90 trading days | C$2.05 | C$1.25 โ C$3.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as TelyRx Holdings Inc. faces challenges, including a widening net loss despite revenue growth. Understanding the implications of these financial results is crucial for making informed decisions.
TelyRx Holdings Inc. suffers a 6.12% drop in one trading day.
The stock's decline comes amid increasing revenues but persistent losses, highlighting the volatility in TelyRx's financial performance.
Bull case
Despite the recent drop, TelyRx has shown impressive revenue growth year-over-year, which suggests there may be potential for recovery and future profitability.
Bear case
However, the widening net loss raises concerns about the company's financial health. This situation could deter investors and lead to further declines in stock price.
Understanding the Decline
On the latest trading day, TelyRx Holdings Inc. saw its stock price decrease significantly, closing at CA$2.30. The 6.12% drop raises concerns among investors about the company's financial trajectory, especially given the recent earnings reports that indicate a widening net loss despite a notable increase in revenue.
Financial Performance Overview
TelyRx reported a revenue increase to CA$19.4 million for Q1 2026, up from CA$6.9 million in Q1 2025. However, the net loss for the same period widened to CA$4.7 million, which may have contributed to the stock's decline. Investors should closely monitor these financial metrics as they reflect the company's operational challenges. For more details, visit our TelyRx stock page.
Market Sentiment and Future Outlook
The market's reaction to TelyRx's financial results suggests a cautious sentiment among investors. While the revenue growth is promising, the persistent losses could lead to further volatility in the stock price. Investors are encouraged to stay informed about future earnings reports and market developments to better assess the company's potential. For ongoing updates, check our TelyRx stock insights.
Advertisement
